Valuation : Lee's Pharmaceutical Holdings Limited

Market Cap 659M 84.13M 72.21M 67.78M 61.9M 117M 8.02B 117M 802M 311M 4.05B 316M 309M 13.41B P/E 2024
8.98x
P/E 2025 9.74x
Enterprise Value 620M 79.08M 67.87M 63.7M 58.18M 110M 7.54B 110M 754M 292M 3.8B 297M 290M 12.6B EV / Sales 2024
0.6x
EV / Sales 2025 0.6x
Free-Float
50.73%
Yield 2024
3.17%
Yield 2025 2.96%
1 year 0.19
Extreme 0.1903
0.19
3 years 0.19
Extreme 0.1882
0.19
5 years 0
Extreme 0.0001
0.35
10 years 0
Extreme 0.0001
0.35
Manager TitleAgeSince
Chief Executive Officer 73 1997-03-31
Director of Finance/CFO 53 2014-10-06
Chief Tech/Sci/R&D Officer 44 -
Director TitleAgeSince
Chairman 70 2010-04-04
Director/Board Member 73 2001-11-30
Director/Board Member 63 2003-08-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.12%-.--% - - 84.13M
-3.59%-7.10%+61.60%+114.83% 1,060B
-1.15%-1.25%+52.98%+62.41% 651B
-1.09%-1.15%+26.18%+79.22% 465B
-0.79%-1.83%+38.99%+40.85% 365B
-1.05%-0.41%+23.38%+39.09% 300B
-0.47%+0.86%+2.37%+12.49% 258B
-0.43%-0.46%+52.06%+71.75% 238B
-2.41%+0.29%-16.74%-54.06% 210B
-0.46%+0.33%+29.05%+92.67% 184B
Average -1.00%-0.66%+29.99%+51.03% 414.49B
Weighted average by Cap. -1.71%-2.16%+39.68%+67.49%

Financials

2024 2025
Net sales 1.4B 179M 153M 144M 131M 248M 17.03B 249M 1.7B 660M 8.59B 671M 656M 28.46B 1.44B 183M 157M 148M 135M 254M 17.47B 256M 1.75B 677M 8.81B 688M 673M 29.19B
Net income 93.1M 11.88M 10.19M 9.57M 8.74M 16.49M 1.13B 16.57M 113M 43.88M 571M 44.59M 43.62M 1.89B 91.94M 11.73M 10.07M 9.45M 8.63M 16.29M 1.12B 16.36M 112M 43.33M 564M 44.04M 43.08M 1.87B
Net Debt 10.45M 1.33M 1.14M 1.07M 981K 1.85M 127M 1.86M 12.71M 4.93M 64.16M 5.01M 4.9M 213M -39.63M -5.06M -4.34M -4.07M -3.72M -7.02M -482M -7.05M -48.2M -18.68M -243M -18.98M -18.57M -806M
Logo Lee's Pharmaceutical Holdings Limited
Lee's Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacturing, marketing and sales of pharmaceutical products. The Company operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The Company's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The Company mainly operates its business in mainland China, Hong Kong and Taiwan.
Employees
1,094

Net sales - Rate of surprise